Program Description
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disease characterized by the degeneration of motor neurons in the brain and spinal cord, which leads to substantial physical disability and is associated with a high mortality rate. Although there is no cure, there are currently 3 FDA-approved therapeutic classes of medication that provide symptomatic relief and slow disease progression for those with ALS. Managed care pharmacists must consider factors such as drug acquisition and reimbursement costs, expanded use of pharmacoeconomic models, and market and regulatory changes, as well as remain up-to-date on new therapy approvals, drug safety warnings, and guideline recommendations so patients with ALS may receive individualized therapy. This activity will provide managed care pharmacists with the knowledge of the current landscape of ALS management including unmet needs related to optimization of care, evaluate real-world data, and provide considerations for future drug approvals.
Target audience: Managed care pharmacists
Type of activity: Application
Learner level: Foundational, intermediate
Release date: May 25, 2023
Expiration date: June 12, 2024
Time to complete activity: 3.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the pathogenesis, incidence, risk factors, clinical presentation, and health and economic burdens associated with amyotrophic lateral sclerosis (ALS) for patients and caregivers
- Explore the efficacy and safety of current and emerging therapies for the treatment of ALS
- Identify the pivotal roles of managed care professionals in expanding efforts to ensure early diagnosis and prompt clinical intervention for management of ALS
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
